ClinicalTrials.gg

Program

HB0056

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Asthma, led by Shanghai Huaota Biopharmaceutical.

Furthest: phase 2, since Sep 5, 20253 company-led studies, 2 open or runningNext primary completion: Aug 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Huaota Biopharmaceutical32 open or runningphase 2since Sep 5, 2025Sep 23, 2024Aug 1, 2027phase 2 · NCT07899996

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2024First study: phase 1 study in HealthyFirst studyNCT06612970 · 46 enrolled · New Zealand
  2. Sep 5, 2025Phase 2 study in AsthmaNCT07899996 · 160 planned · China
  3. Oct 27, 2026Phase 2 study in Idiopathic Pulmonary FibrosisNCT07909655 · 75 planned · China

Ahead

  1. Aug 1, 2027Primary completion: phase 2 study in AsthmaNCT07899996
  2. Jan 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07909655

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07909655Idiopathic Pulmonary Fibrosis · China2Not yet recruitingJan 202875
NCT07899996Asthma · China2RecruitingAug 1, 2027160
NCT06612970Healthy · New Zealand1CompletedJun 13, 202546

How it is read

Names in the registry

  • “HB0056”, 4 entries

Codes read as this program: HB0056.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.